CryoCath Technologies Inc.,
Medical Devices & Tech  Advamed Member
16771 Chemin Ste-Marie
Montreal, Quebec H9H 5H3 Canada
phone: 514 694 1212
fax: 514 694 6279
Symbol CYT
Exchange TSE
Founded 0
Employees
www.cryocath.com
Research Sector Medical Devices & Tech
Summary Description
Catheter-based products for the cryotherapeutic treatment of cardiovascular disease.
Management
Jan Keltjens [Bio], President, Chief Executive Officer; Derek Lindsay, Chief Financial Officer; Jean-Pierre Desmarais, Chief Scientific Officer; Marwan Abboud, Vice President, Technology & Intellectual Property; Robert Mattioli, Vice-President, Global Sales; Allan Zingeler, Vice-President, Global Marketing; Olivier Bataille, Vice-President, Product Development; Guy Rodomista, Vice-President, Operations; Beatrice Despotopoulos, Senior Director, Human Resources
Ownership
Financials Mkt Cap :1


* numbers in thousands

 
Keywords
cardiovascular, Cardiology, cardiac, heart, heart, electrophysiology

Comment | Printable Version | Nov. 01, 2008
If you work for CryoCath Technologies Inc., and want to update this profile, click here


Description
Cryoablation is an alternative treatment for arrhythmia, especially in proximity to critical structures in the heart where safety is vital.
Products / Services
Freezor is a flexible, single-use, minimally invasive cardiac CryoAblation catheter designed to create focal lesions to treat AVNRT. Freezor Xtra Surgical Cardiac CryoAblation Device is designed for minimally invasive cardiac surgery procedures, including the surgical treatment of cardiac arrhythmias. An advanced microprocessor-based electromechanical refrigeration console controls our CryoTherapy system, including the FreezorŪ family Freezor MAX Surgical Cardiac CryoAblation Device is designed for minimally invasive cardiac surgery procedures, including the surgical treatment of cardiac arrhythmias.
Technology / Differentiation
CryoTherapy offers an alternative treatment option. CryoTherapy is associated with thermal reversibility and precision when working around the AV node. A number of key features are associated with the use of CryoTherapy for ablating tissue responsible for arrhythmias, including: * uniquely stable handling (due to CryoAdhesion) * site testing by creating a reversible thermal effect * preservation of tissue integrity * reduced risk of thrombosis and stenosis


2008-11-23-752